The Trump administration on Thursday announced its newest pharmaceutical agreement under its Most Favored Nation (MFN) policy, striking deals with Novo Nordisk and Eli Lilly to sell their GLP-1 products at discounted prices. According to senior administration officials, the two manufacturers have agreed to sell their injectable GLP-1 products for a monthly starting price starting of $245 for people on Medicare and Medicaid, as well...
Treating gum disease could reduce risk of heart attacks and strokes, study suggests
- today, 12:00 PM
- foxnews.com
- 0
No comments